research Follicular Disorders
The document concludes that proper diagnosis and treatment of follicular disorders are crucial, with specific treatments for conditions like acne, drug-induced eruptions, and rosacea.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.
research DERMATOLOGICAL ADVERSE EFFECTS OF CHEMOTHERAPEUTIC AGENTS: EXPERIENCE FROM A TERTIARY CENTRE
About 22% of cancer patients had skin-related side effects from chemotherapy, but these were usually not severe enough to halt treatment.
research Glossary
research General Dermatology
The document explains various skin conditions and their treatments.
research Onychomatricoma: Clinical presentation and management
The treatments for fungal nail infection, hair loss in men, benign nail tumor, and chemotherapy-associated nail bed inflammation are effective and safe.
research Povidone-iodine nail solution is active in treating chemotherapy-associated paronychia
Povidone-iodine nail solution effectively treats nail infections caused by chemotherapy.
research Long-term treatment within a maximum of 96 weeks of tinea unguium with long-pulsed neodymium-doped yttrium aluminum garnet laser
Laser treatment is safe and can effectively treat toenail fungus, especially when combined with other treatments if no improvement is seen after about a year.
research Drug Eruptions
Any medication can cause skin reactions, some due to allergies and others due to dosage or genetic factors.
research Subject Index
The document lists various dermatology topics, treatments, and diagnostic methods.
research Alopecias
The document concludes that non-scarring alopecias can be reversed, but scarring alopecias cause permanent hair loss.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim
New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research Data from Targeting Superficial or Nodular Basal Cell Carcinoma with Topically Formulated Small Molecule Inhibitor of Smoothened
The treatment was ineffective in humans.
research Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
research Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
research Clinical efficacy and safety of Kanglaite injection, adjuvant cemcitabine and cisplatin chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis
Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.
research SUN-911 Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
research The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
Nanomaterials in biomedicine can improve treatments but may have risks like toxicity, needing more safety research.
research Epidermal growth factor, innovation and safety
Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.
research Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
Some drugs, especially biologics, can cause skin reactions that look like other skin diseases, and stopping the drug usually helps clear up these reactions.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial
Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
research Bexxar, iodine I 131 tositumomab, Effective in Long Term Follow-up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.